Title |
Bosutinib: a SRC–ABL tyrosine kinase inhibitor for treatment of chronic myeloid leukemia
|
---|---|
Published in |
Pharmacogenomics and Personalized Medicine, August 2013
|
DOI | 10.2147/pgpm.s32145 |
Pubmed ID | |
Authors |
Fuad El Rassi, Hanna Jean Khoury |
Abstract |
Bosutinib is one of five tyrosine kinase inhibitors commercially available in the United States for the treatment of chronic myeloid leukemia. This review of bosutinib summarizes the mode of action, pharmacokinetics, efficacy and safety data, as well as the patient-focused perspective through quality-of-life data. Bosutinib has shown considerable and sustained efficacy in chronic myeloid leukemia, especially in the chronic phase, with resistance or intolerance to prior tyrosine kinase inhibitors. Bosutinib has distinct but manageable adverse events. In the absence of T315I and V299L mutations, there are no absolute contraindications for the use of bosutinib in this patient population. |
X Demographics
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 3 | 100% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Practitioners (doctors, other healthcare professionals) | 3 | 100% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Mexico | 1 | 4% |
United States | 1 | 4% |
Brazil | 1 | 4% |
Unknown | 25 | 89% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Ph. D. Student | 6 | 21% |
Other | 5 | 18% |
Researcher | 4 | 14% |
Student > Postgraduate | 2 | 7% |
Professor | 1 | 4% |
Other | 2 | 7% |
Unknown | 8 | 29% |
Readers by discipline | Count | As % |
---|---|---|
Agricultural and Biological Sciences | 6 | 21% |
Medicine and Dentistry | 5 | 18% |
Biochemistry, Genetics and Molecular Biology | 2 | 7% |
Chemistry | 2 | 7% |
Physics and Astronomy | 1 | 4% |
Other | 3 | 11% |
Unknown | 9 | 32% |